Current status of application of convalescent plasma in acute viral infectious diseases and its prospect in therapy of COVID-19

With the successful application of convalescent plasma(CP) in various acute viral infectious diseases, the unique advantage of the therapy has been paid more and more attentions. Recently, a novel coronavirus named as 2019-nCoV(SARS-CoV-2) was discovered and identified in Wuhan, China. Up to now, there has been no specific treatment for 2019-nCoV(SARS-CoV-2) infection. This paper describes the current status of application of CP in Ebola, pandemic influenza, severe acute respiratory syndrome(SARS) and Middle East respiratory syndrome(MERS) as well as the prospect of CP in therapy of COVID-19.